PMID- 29564716
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 9
IP  - 3
DP  - 2018 Jun
TI  - The Postprandial-to-Fasting Serum C-Peptide Ratio is a Predictor of Response to 
      Basal Insulin-Supported Oral Antidiabetic Drug(s) Therapy: A Retrospective 
      Analysis.
PG  - 963-971
LID - 10.1007/s13300-018-0404-6 [doi]
AB  - INTRODUCTION: Basal insulin is widely recommended for the treatment of type 2 
      diabetes mellitus (T2DM) patients who are unable to achieve glycemic control with 
      oral antidiabetic drug(s) (OADs). However, some patients are still unable to 
      control their blood glucose levels even when on basal insulin-supported OAD(s) 
      therapy (BOT). The aim of this study was to investigate the factor(s) predicting 
      patient response to BOT. METHODS: A total of 212 patients with T2DM, ranging in 
      age from 18 to 65 years, admitted to the university hospital of Sun Yat-sen 
      University, Guangzhou, China, were enrolled in the study between January 2013 and 
      July 2016. All patients had fasting blood glucose levels of >/= 10.0 mmol/L despite 
      receiving OAD(s) treatment. According to study design, these patients first 
      received intensive insulin therapy for 2 weeks to attain and maintain their 
      glycemic goals and then were switched to BOT. Responders were defined as subjects 
      who maintained their glycemic targets with BOT for at least 3 months; all others 
      were considered to be non-responders. The characteristics between responders and 
      non-responders were compared. RESULTS: Compared with non-responders, responders 
      had a shorter duration of diabetes (5.1 +/- 5.0 vs. and 10.1 +/- 3.2 years; 
      P  < 0.001) and a higher 2-h postprandial C-peptide-to-fasting C-peptide ratio (2 
      h-PCP/FCP: 1.95 +/- 0.51 vs. 1.67 +/- 0.32; P  < 0.01). Responders showed a lower 
      proportion of previous treatment with insulin (69/100 vs 40/3; P  < 0.001) and 
      sulfonlureas or glinides (116/50 vs 40/0; P <0.001) than non-responders. 
      Multivariate logistic regression analysis showed that previous insulin treatment 
      (odds ratio [OR] 17.677, 95% confidence interval [CI] 5.205-60.027; P  < 0.001) 
      and the 2 h-PCP/FCP ratio (OR 0.241, 95% CI 0.058-0.679; P  = 0.007) had 
      predictive value. CONCLUSIONS: A higher 2 h-PCP/FCP ratio and a lack of previous 
      insulin treatment increase the likelihood of BOT success.
FAU - Mu, Pan-Wei
AU  - Mu PW
AUID- ORCID: 0000-0001-5413-6876
AD  - Department of Endocrinology, The Third Affiliated Hospital of Sun Yat-sen 
      University, Guangzhou, 510630, People's Republic of China.
FAU - Liu, De-Zhao
AU  - Liu DZ
AD  - Department of Anesthesia, The Third Affiliated Hospital of Sun Yat-sen 
      University, Guangzhou, 510630, People's Republic of China.
FAU - Lin, Ying
AU  - Lin Y
AD  - Department of Gastroenterology, The Third Affiliated Hospital of Sun Yat-sen 
      University, Guangzhou, 510630, People's Republic of China.
FAU - Liu, Dong
AU  - Liu D
AD  - Department of Endocrinology, The Fifth Affiliated Hospital of ZUNYI Medical 
      University, Zhuhai, 519170, People's Republic of China.
FAU - Zhang, Fan
AU  - Zhang F
AD  - Department of Endocrinology, The Third Affiliated Hospital of Sun Yat-sen 
      University, Guangzhou, 510630, People's Republic of China.
FAU - Zhang, Yong-Jun
AU  - Zhang YJ
AD  - Department of Endocrinology, The Fifth Affiliated Hospital of ZUNYI Medical 
      University, Zhuhai, 519170, People's Republic of China.
FAU - Lin, Shuo
AU  - Lin S
AD  - Department of Endocrinology, The Third Affiliated Hospital of Sun Yat-sen 
      University, Guangzhou, 510630, People's Republic of China.
FAU - Wang, Lin-Qin
AU  - Wang LQ
AD  - Nansha Hospital of Traditional Chinese Medicine, Guangzhou, 511462, People's 
      Republic of China.
FAU - Wang, Man-Man
AU  - Wang MM
AD  - Department of Endocrinology, The Third Affiliated Hospital of Sun Yat-sen 
      University, Guangzhou, 510630, People's Republic of China.
FAU - Shu, Jiong
AU  - Shu J
AD  - Department of Endocrinology, The Third Affiliated Hospital of Sun Yat-sen 
      University, Guangzhou, 510630, People's Republic of China.
FAU - Zeng, Long-Yi
AU  - Zeng LY
AD  - Department of Endocrinology, The Third Affiliated Hospital of Sun Yat-sen 
      University, Guangzhou, 510630, People's Republic of China.
FAU - Chen, Yan-Ming
AU  - Chen YM
AD  - Department of Endocrinology, The Third Affiliated Hospital of Sun Yat-sen 
      University, Guangzhou, 510630, People's Republic of China. yanmingch@qq.com.
LA  - eng
GR  - 2015015/5010 Clinical Research Projects of Sun Yat-sen University/
GR  - 2016A050502010/the Science and Technology Plan Projects of Guangdong Province/
GR  - 201604020016/the Key Special Projects of Medical and Health Collaborative 
      Innovation of Guangzhou City/
GR  - 2060404/the Special Scientific Research Project of Guangzhou City/
GR  - 2017YFA0105803/National Key R&D Program of China/
GR  - 81770826/General Program of National Natural Science Foundation of China/
PT  - Journal Article
DEP - 20180321
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
PMC - PMC5984910
OTO - NOTNLM
OT  - Basal insulin
OT  - C-peptide
OT  - Predictor
OT  - Type 2 diabetes mellitus
EDAT- 2018/03/23 06:00
MHDA- 2018/03/23 06:01
PMCR- 2018/03/21
CRDT- 2018/03/23 06:00
PHST- 2018/01/23 00:00 [received]
PHST- 2018/03/23 06:00 [pubmed]
PHST- 2018/03/23 06:01 [medline]
PHST- 2018/03/23 06:00 [entrez]
PHST- 2018/03/21 00:00 [pmc-release]
AID - 10.1007/s13300-018-0404-6 [pii]
AID - 404 [pii]
AID - 10.1007/s13300-018-0404-6 [doi]
PST - ppublish
SO  - Diabetes Ther. 2018 Jun;9(3):963-971. doi: 10.1007/s13300-018-0404-6. Epub 2018 
      Mar 21.